Coasting vs gonadotrophin‐releasing hormone antagonist
- Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 190 participantsVery low
The review found no eligible studies for this question.
Coasting showed no clear difference in clinical Pregnancy compared with gonadotrophin‐releasing hormone antagonist (low certainty).
It is very uncertain whether coasting changes multiple pregnancy compared with gonadotrophin‐releasing hormone antagonist (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether coasting changes OHSS compared with follicle stimulating hormone administration at time of hCG (very low certainty).
The review found no eligible studies for this question.
Coasting showed no clear difference in clinical Pregnancy compared with follicle stimulating hormone administration at time of hCG (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether coasting changes live birth compared with no coasting (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether coasting changes OHSS compared with cabergoline (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether coasting changes clinical pregnancy rate compared with cabergoline (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Coasting showed no clear difference in clinical pregnancy compared with no coasting (low certainty).
Coasting may leads to lower multiple pregnancy compared with no coasting (low certainty).
It is very uncertain whether coasting changes miscarriage compared with no coasting (very low certainty).
It is very uncertain whether coasting changes OHSS compared with early unilateral follicular aspiration (very low certainty).